{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:23Z","timestamp":1790704343859,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00520-022-07480-x","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:05:58Z","timestamp":1671149158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Multinational Association of Supportive Care in Cancer (MASCC) expert opinion\/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Bryony","family":"Alderman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Bouleuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory B.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"de Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberson","family":"Tanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Garsed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellar","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"7480_CR1","unstructured":"World Health Organisation. Alcohol, drugs and addictive behaviours unit. Cannabis. Available from: https:\/\/www.who.int\/teams\/mental-health-and-substance-use\/alcohol-drugs-and-addictive-behaviours\/drugs-psychoactive\/cannabis [Accessed 8th March 2022]"},{"issue":"3","key":"7480_CR2","first-page":"180","volume":"42","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB, Abazia DT (2017) Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T 42(3):180\u2013188","journal-title":"P T"},{"issue":"5","key":"7480_CR3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamaoncol.2016.0155","volume":"2","author":"G Wilkie","year":"2016","unstructured":"Wilkie G, Sakr B, Rizack T (2016) Medical marijuana use in oncology: a review. JAMA Oncol 2(5):670\u2013675. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0155","journal-title":"JAMA Oncol"},{"key":"7480_CR4","unstructured":"Multinational Association of Supportive Care in Cancer, 2018. Recommendations for MASCC guideline construction and the endorsement of externally generated guidelines. Available from: https:\/\/www.mascc.org\/assets\/Toolbox\/PoliciesForms\/mascc_guideline_policy_2018.pdf [Accessed 15th January 2022]"},{"issue":"16","key":"7480_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJM197510162931603","volume":"293","author":"SE Sallan","year":"1975","unstructured":"Sallan SE, Zinberg NE, Frei E 3rd (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293(16):795\u2013797. https:\/\/doi.org\/10.1056\/NEJM197510162931603","journal-title":"N Engl J Med"},{"issue":"6","key":"7480_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","volume":"91","author":"AE Chang","year":"1979","unstructured":"Chang AE, Shiling DJ, Stillman RC et al (1979) Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91(6):819\u2013824. https:\/\/doi.org\/10.7326\/0003-4819-91-6-819","journal-title":"Ann Intern Med"},{"issue":"5","key":"7480_CR7","first-page":"338","volume":"21","author":"JC Kluin-Neleman","year":"1979","unstructured":"Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA (1979) delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol 21(5):338\u2013340","journal-title":"Vet Hum Toxicol"},{"issue":"7","key":"7480_CR8","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::aid-cncr2820470704>3.0.co;2-4","volume":"47","author":"AE Chang","year":"1981","unstructured":"Chang AE, Shiling DJ, Stillman RC et al (1981) A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47(7):1746\u20131751. https:\/\/doi.org\/10.1002\/1097-0142(19810401)47:7%3c1746::aid-cncr2820470704%3e3.0.co;2-4","journal-title":"Cancer"},{"issue":"6","key":"7480_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","volume":"91","author":"S Frytak","year":"1979","unstructured":"Frytak S, Moertel CG, O\u2019Fallon JR et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med. 91(6):825\u2013830. https:\/\/doi.org\/10.7326\/0003-4819-91-6-825","journal-title":"Ann Intern Med."},{"issue":"4","key":"7480_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/1097-0142(19820815)50:4<636::aid-cncr2820500404>3.0.co;2-4","volume":"50","author":"JT Ungerleider","year":"1982","unstructured":"Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K (1982) Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50(4):636\u2013645. https:\/\/doi.org\/10.1002\/1097-0142(19820815)50:4%3c636::aid-cncr2820500404%3e3.0.co;2-4","journal-title":"Cancer"},{"issue":"S1","key":"7480_CR11","doi-asserted-by":"publisher","first-page":"76S","DOI":"10.1002\/j.1552-4604.1981.tb02578.x","volume":"21","author":"LE Orr","year":"1981","unstructured":"Orr LE, McKernan JF (1981) Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 21(S1):76S-80S. https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb02578.x","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"7480_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00175407","volume":"6","author":"M McCabe","year":"1988","unstructured":"McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS (1988) Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6(3):243\u2013246. https:\/\/doi.org\/10.1007\/BF00175407","journal-title":"Invest New Drugs"},{"issue":"6","key":"7480_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/00000421-199012000-00006","volume":"13","author":"M Lane","year":"1990","unstructured":"Lane M, Smith FE, Sullivan RA, Plasse TF (1990) Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 13(6):480\u2013484. https:\/\/doi.org\/10.1097\/00000421-199012000-00006","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"7480_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/0885-3924(91)90026-z","volume":"6","author":"M Lane","year":"1991","unstructured":"Lane M, Vogel CL, Ferguson J et al (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6(6):352\u2013359. https:\/\/doi.org\/10.1016\/0885-3924(91)90026-z","journal-title":"J Pain Symptom Manage"},{"issue":"6 I","key":"7480_CR15","first-page":"1014","volume":"33","author":"S Kleinman","year":"1983","unstructured":"Kleinman S, Weitzman SA, Cassem N, Andrews E (1983) Double blind trial of delta-9-tetrahydrocannabinol (THC) versus placebo as an adjunct to prochlorperazine for chemotherapy-induced vomiting. Curr Ther Res-Clin Exp 33(6 I):1014\u20137","journal-title":"Curr Ther Res-Clin Exp"},{"issue":"S1","key":"7480_CR16","doi-asserted-by":"publisher","first-page":"38S","DOI":"10.1002\/j.1552-4604.1981.tb02571.x","volume":"21","author":"JA Neidhart","year":"1981","unstructured":"Neidhart JA, Gagen MM, Wilson HE, Young DC (1981) Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 21(S1):38S-42S. https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb02571.x","journal-title":"J Clin Pharmacol"},{"issue":"662","key":"7480_CR17","first-page":"449","volume":"91","author":"BM Colls","year":"1980","unstructured":"Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG (1980) The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 91(662):449\u2013451","journal-title":"N Z Med J"},{"issue":"5","key":"7480_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/bjc.1983.247","volume":"48","author":"S Ahmedzai","year":"1983","unstructured":"Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48(5):657\u2013663. https:\/\/doi.org\/10.1038\/bjc.1983.247","journal-title":"Br J Cancer"},{"issue":"4","key":"7480_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00000421-198508000-00013","volume":"8","author":"A Niiranen","year":"1985","unstructured":"Niiranen A, Mattson K (1985) A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8(4):336\u2013340. https:\/\/doi.org\/10.1097\/00000421-198508000-00013","journal-title":"Am J Clin Oncol"},{"issue":"Suppl B","key":"7480_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0305-7372(82)80035-2","volume":"9","author":"SE Jones","year":"1982","unstructured":"Jones SE, Durant JR, Greco FA, Robertone A (1982) A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 9(Suppl B):45\u201348. https:\/\/doi.org\/10.1016\/s0305-7372(82)80035-2","journal-title":"Cancer Treat Rev."},{"issue":"Suppl B","key":"7480_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0305-7372(82)80032-7","volume":"9","author":"R Johansson","year":"1982","unstructured":"Johansson R, Kilkku P, Groenroos M (1982) A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev. 9(Suppl B):25\u201333. https:\/\/doi.org\/10.1016\/s0305-7372(82)80032-7","journal-title":"Cancer Treat Rev."},{"issue":"23","key":"7480_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","volume":"300","author":"TS Herman","year":"1979","unstructured":"Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300(23):1295\u20131297. https:\/\/doi.org\/10.1056\/NEJM197906073002302","journal-title":"N Engl J Med"},{"issue":"11","key":"7480_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison P, Mersiades A, Kirby A et al (2020) Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 31(11):1553\u20131560. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.020","journal-title":"Ann Oncol"},{"issue":"S1","key":"7480_CR24","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1002\/j.1552-4604.1981.tb02576.x","volume":"21","author":"LH Einhorn","year":"1981","unstructured":"Einhorn LH, Nagy C, Furnas B, Williams SD (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21(S1):64S-69S. https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb02576.x","journal-title":"J Clin Pharmacol"},{"issue":"Suppl B","key":"7480_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0305-7372(82)80036-4","volume":"9","author":"M Levitt","year":"1982","unstructured":"Levitt M (1982) Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev 9(Suppl B):49\u201353","journal-title":"Cancer Treat Rev"},{"issue":"2\u20133","key":"7480_CR26","first-page":"219","volume":"64","author":"N Steele","year":"1980","unstructured":"Steele N, Gralla RJ, Braun DW Jr, Young CW (1980) Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64(2\u20133):219\u2013224","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"7480_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF02934575","volume":"3","author":"SM Crawford","year":"1986","unstructured":"Crawford SM, Buckman R (1986) Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 3(1):39\u201342. https:\/\/doi.org\/10.1007\/BF02934575","journal-title":"Med Oncol Tumor Pharmacother"},{"issue":"3","key":"7480_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00256701","volume":"17","author":"M Pomeroy","year":"1986","unstructured":"Pomeroy M, Fennelly JJ, Towers M (1986) Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 17(3):285\u2013288. https:\/\/doi.org\/10.1007\/BF00256701","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"7480_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/BF01728184","volume":"64","author":"N Niederle","year":"1986","unstructured":"Niederle N, Sch\u00fctte J, Schmidt CG (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 64(8):362\u2013365. https:\/\/doi.org\/10.1007\/BF01728184","journal-title":"Klin Wochenschr"},{"issue":"Suppl B","key":"7480_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0305-7372(82)80034-0","volume":"9","author":"JK Wada","year":"1982","unstructured":"Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE (1982) Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev. 9(Suppl B):39\u201344. https:\/\/doi.org\/10.1016\/s0305-7372(82)80034-0","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"7480_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1185\/030079907x167525","volume":"23","author":"E Meiri","year":"2007","unstructured":"Meiri E, Jhangiani H, Vredenburgh JJ et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23(3):533\u2013543. https:\/\/doi.org\/10.1185\/030079907x167525","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"7480_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03743.x","volume":"70","author":"M Duran","year":"2010","unstructured":"Duran M, P\u00e9rez E, Abanades S et al (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70(5):656\u2013663. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03743.x","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"7480_CR33","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/0277-5379(83)90032-9","volume":"19","author":"AW Hutcheon","year":"1983","unstructured":"Hutcheon AW, Palmer JB, Soukop M et al (1983) A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 19(8):1087\u20131090. https:\/\/doi.org\/10.1016\/0277-5379(83)90032-9","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"5","key":"7480_CR34","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00520-019-05280-4","volume":"28","author":"R Chow","year":"2020","unstructured":"Chow R, Valdez C, Chow N et al (2020) Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. Support Care Cancer 28(5):2095\u20132103. https:\/\/doi.org\/10.1007\/s00520-019-05280-4","journal-title":"Support Care Cancer"},{"issue":"11","key":"7480_CR35","doi-asserted-by":"publisher","first-page":"CD009464","DOI":"10.1002\/14651858.CD009464.pub2","volume":"2015","author":"LA Smith","year":"2015","unstructured":"Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015(11):CD009464. https:\/\/doi.org\/10.1002\/14651858.CD009464.pub2","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"7480_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1365-2354.2008.00917.x","volume":"17","author":"FC Machado Rocha","year":"2008","unstructured":"Machado Rocha FC, St\u00e9fano SC, De C\u00e1ssia HR, Rosa Oliveira LM, Da Silveira DX (2008) Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 17(5):431\u2013443. https:\/\/doi.org\/10.1111\/j.1365-2354.2008.00917.x","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"7303","key":"7480_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/bmj.323.7303.16","volume":"323","author":"MR Tram\u00e8r","year":"2001","unstructured":"Tram\u00e8r MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323(7303):16\u201321. https:\/\/doi.org\/10.1136\/bmj.323.7303.16","journal-title":"BMJ"},{"issue":"4","key":"7480_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/0277-5379(88)90300-8","volume":"24","author":"D Cunningham","year":"1988","unstructured":"Cunningham D, Bradley CJ, Forrest GJ et al (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24(4):685\u2013689. https:\/\/doi.org\/10.1016\/0277-5379(88)90300-8","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"6","key":"7480_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s0009-9260(82)80383-8","volume":"33","author":"HH Lucraft","year":"1982","unstructured":"Lucraft HH, Palmer MK (1982) Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 33(6):621\u2013622. https:\/\/doi.org\/10.1016\/s0009-9260(82)80383-8","journal-title":"Clin Radiol"},{"issue":"21","key":"7480_CR40","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","volume":"24","author":"F Strasser","year":"2006","unstructured":"Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24(21):3394\u20133400. https:\/\/doi.org\/10.1200\/JCO.2005.05.1847","journal-title":"J Clin Oncol"},{"issue":"9","key":"7480_CR41","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","volume":"26","author":"JG Turcott","year":"2018","unstructured":"Turcott JG, Del Roc\u00edo Guillen N\u00fa\u00f1ez M, Flores-Estrada D et al (2018) The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 26(9):3029\u20133038. https:\/\/doi.org\/10.1007\/s00520-018-4154-9","journal-title":"Support Care Cancer"},{"issue":"2","key":"7480_CR42","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","volume":"20","author":"A Jatoi","year":"2002","unstructured":"Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20(2):567\u2013573. https:\/\/doi.org\/10.1200\/JCO.2002.20.2.567","journal-title":"J Clin Oncol"},{"issue":"9","key":"7480_CR43","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/annonc\/mdq727","volume":"22","author":"TD Brisbois","year":"2011","unstructured":"Brisbois TD, de Kock IH, Watanabe SM et al (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22(9):2086\u20132093. https:\/\/doi.org\/10.1093\/annonc\/mdq727","journal-title":"Ann Oncol"},{"issue":"4","key":"7480_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1634\/theoncologist.2018-0383","volume":"24","author":"T Taha","year":"2019","unstructured":"Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G (2019) Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. Oncologist 24(4):549\u2013554","journal-title":"Oncologist"},{"issue":"1","key":"7480_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer 25(1):289\u2013294. https:\/\/doi.org\/10.1007\/s00520-016-3365-1","journal-title":"Support Care Cancer"},{"issue":"1","key":"7480_CR46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D et al (2017) 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25(1):277\u2013288. https:\/\/doi.org\/10.1007\/s00520-016-3313-0","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07480-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T04:21:31Z","timestamp":1674015691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07480-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["7480"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07480-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}